Key result
Hepatitis E virus-associated neuralgic amyotrophy presented with significantly more bilateral involvement (80.0% vs 8.6%, p<0.001) and damage outside the brachial plexus than non-HEV cases.
Why the study?
Does HEV infection alter the clinical phenotype and outcome in patients with neuralgic amyotrophy?
Population
118 patients with neuralgic amyotrophy, including 57 cases of HEV-associated NA and 61 NA cases without HEV…
Comparison
Hepatitis E virus (HEV) infection (exposure) vs Neuralgic amyotrophy without evidence of HEV…
Design
Cohort
Follow-up
median 11.5 to 12 months
Authors
Loading...
HEV testing may be considered in bilateral neuralgic amyotrophy; leaves open effects on management and prognosis.
Case-Control (n=118)
Yes
Does HEV infection alter the clinical phenotype and outcome in patients with neuralgic amyotrophy?
Absolute Event Rate: 80% vs 8.6%
p-value: p=< 0.001
HEV-associated neuralgic amyotrophy presents with a distinct, more extensive clinical phenotype including bilateral and extra-brachial involvement, though long-term functional outcomes are similar to idiopathic cases.
Eijk et al. (2017) conducted a case-control in Neuralgic amyotrophy (n=118). Hepatitis E virus infection vs. No evidence of HEV infection was evaluated on Bilateral involvement (p=< 0.001). Hepatitis E virus-associated neuralgic amyotrophy presented with significantly more bilateral involvement (80.0% vs 8.6%, p<0.001) and damage outside the brachial plexus than non-HEV cases.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: